ABSTRACT

India is emerging as a strategic hub for GLP-1-based therapies amid rising obesity and diabetes rates. With a large treatment-naïve population, evolving regulatory frameworks, and upcoming patent expirations (like semaglutide in 2026), the country offers immense commercial potential for pharmaceutical companies. However, regulatory conservatism, pricing unpredictability, and market complexity pose major challenges.

This whitepaper explores how forward-looking pharma firms can overcome these barriers using real-time Regulatory Intelligence (RI). From navigating CDSCO and NPPA policies to anticipating pricing shifts and tracking competitor filings, RI serves as a critical enabler for market access, speed-to-market, and strategic differentiation.

Download to explore actionable strategies for leveraging RI to unlock India’s dynamic GLP-1 opportunity—before the next wave of generics arrives.